US FDA Approves AstraZeneca-Amgen Drug for Severe Asthma

The logo of AstraZeneca outside its North America headquarters in Wilmington, Del., on March 22, 2021. Rachel Wisniewski/Reuters

The U.S. Food and Drug Administration (FDA) approved AstraZeneca and Amgen’s drug, Tezspire, to treat severe asthma for those aged 12 years and older, the companies said on Friday.

The approval is based on late-stage trial data that showed the drug cut the rate of asthma attacks by 56 percent among patients when compared with placebo.